MA55199B1 - (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques - Google Patents
(n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiquesInfo
- Publication number
- MA55199B1 MA55199B1 MA55199A MA55199A MA55199B1 MA 55199 B1 MA55199 B1 MA 55199B1 MA 55199 A MA55199 A MA 55199A MA 55199 A MA55199 A MA 55199A MA 55199 B1 MA55199 B1 MA 55199B1
- Authority
- MA
- Morocco
- Prior art keywords
- leucine
- pharmaceutically acceptable
- acceptable salt
- acetyl
- brain injury
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812987P | 2019-03-02 | 2019-03-02 | |
| US201962842296P | 2019-05-02 | 2019-05-02 | |
| US201962888894P | 2019-08-19 | 2019-08-19 | |
| US201962895144P | 2019-09-03 | 2019-09-03 | |
| EP20712029.6A EP3934637B1 (en) | 2019-03-02 | 2020-03-02 | (n-)acetyl-l-leucine for use in treating traumatic brain injury |
| PCT/IB2020/051767 WO2020178721A1 (en) | 2019-03-02 | 2020-03-02 | Leucine, acetyl leucine, and related analogs for treating disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA55199A MA55199A (fr) | 2022-01-12 |
| MA55199B1 true MA55199B1 (fr) | 2024-08-30 |
Family
ID=69845470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA55199A MA55199B1 (fr) | 2019-03-02 | 2020-03-02 | (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220142959A1 (https=) |
| EP (2) | EP4464378A3 (https=) |
| JP (2) | JP7555346B2 (https=) |
| KR (2) | KR102941068B1 (https=) |
| CN (2) | CN119097618A (https=) |
| AU (2) | AU2020231189B2 (https=) |
| BR (1) | BR112021017203A2 (https=) |
| CA (1) | CA3131948A1 (https=) |
| DK (1) | DK3934637T3 (https=) |
| ES (1) | ES2990183T3 (https=) |
| FI (1) | FI3934637T3 (https=) |
| HR (1) | HRP20241150T1 (https=) |
| HU (1) | HUE068527T2 (https=) |
| IL (2) | IL285870B2 (https=) |
| LT (1) | LT3934637T (https=) |
| MA (1) | MA55199B1 (https=) |
| MD (1) | MD3934637T2 (https=) |
| MX (2) | MX2021010568A (https=) |
| PL (1) | PL3934637T3 (https=) |
| PT (1) | PT3934637T (https=) |
| RS (1) | RS65849B1 (https=) |
| SG (1) | SG11202109512SA (https=) |
| SI (1) | SI3934637T1 (https=) |
| SM (1) | SMT202400334T1 (https=) |
| WO (1) | WO2020178721A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| JP7471298B2 (ja) * | 2018-12-06 | 2024-04-19 | イントラビオ エルティーディー | アセチル－ロイシンの重水素化類似体 |
| US20250025442A1 (en) * | 2020-12-10 | 2025-01-23 | Texas Tech University System | BCAA-Lowering Compounds for Prevention and/or Treatment of Alzheimer's Disease and Related Disorders |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
| WO2024243004A2 (en) * | 2023-05-19 | 2024-11-28 | The Children's Hospital Of Philadelphia | Compositions and methods for treating traumatic brain injury |
| WO2025166100A1 (en) * | 2024-02-02 | 2025-08-07 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
| WO2025175092A1 (en) * | 2024-02-14 | 2025-08-21 | Intrabio Inc. | Acetyl leucine for treating syngap1-related disorders |
| WO2025264957A2 (en) * | 2024-06-20 | 2025-12-26 | Intrabio Inc. | Acetyl leucine for treating neurodevelopmental disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| SMT201600385T1 (it) | 2010-06-25 | 2017-03-08 | Shire Human Genetic Therapies | Trasporto di agenti terapeutici all’snc |
| US20140080885A1 (en) * | 2012-09-13 | 2014-03-20 | University Of South Florida (A Florida Non-Profit Corporation) | Methods of treating traumatic brain injury |
| US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| TN2016000259A1 (en) * | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
| WO2018029658A1 (en) * | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| NZ750391A (en) | 2016-08-11 | 2026-03-27 | Intrabio Ltd | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
| WO2019036442A1 (en) | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY |
-
2020
- 2020-03-02 WO PCT/IB2020/051767 patent/WO2020178721A1/en not_active Ceased
- 2020-03-02 SI SI202030476T patent/SI3934637T1/sl unknown
- 2020-03-02 JP JP2021551939A patent/JP7555346B2/ja active Active
- 2020-03-02 PL PL20712029.6T patent/PL3934637T3/pl unknown
- 2020-03-02 KR KR1020217031422A patent/KR102941068B1/ko active Active
- 2020-03-02 SG SG11202109512SA patent/SG11202109512SA/en unknown
- 2020-03-02 DK DK20712029.6T patent/DK3934637T3/da active
- 2020-03-02 SM SM20240334T patent/SMT202400334T1/it unknown
- 2020-03-02 HR HRP20241150TT patent/HRP20241150T1/hr unknown
- 2020-03-02 RS RS20240913A patent/RS65849B1/sr unknown
- 2020-03-02 US US17/435,784 patent/US20220142959A1/en active Pending
- 2020-03-02 CN CN202411228005.XA patent/CN119097618A/zh active Pending
- 2020-03-02 CA CA3131948A patent/CA3131948A1/en active Pending
- 2020-03-02 MA MA55199A patent/MA55199B1/fr unknown
- 2020-03-02 EP EP24188941.9A patent/EP4464378A3/en active Pending
- 2020-03-02 KR KR1020257040124A patent/KR20250171484A/ko active Pending
- 2020-03-02 IL IL285870A patent/IL285870B2/en unknown
- 2020-03-02 CN CN202080029158.5A patent/CN114040757B/zh active Active
- 2020-03-02 BR BR112021017203A patent/BR112021017203A2/pt unknown
- 2020-03-02 EP EP20712029.6A patent/EP3934637B1/en active Active
- 2020-03-02 LT LTEPPCT/IB2020/051767T patent/LT3934637T/lt unknown
- 2020-03-02 FI FIEP20712029.6T patent/FI3934637T3/fi active
- 2020-03-02 AU AU2020231189A patent/AU2020231189B2/en active Active
- 2020-03-02 MD MDE20220032T patent/MD3934637T2/ro unknown
- 2020-03-02 MX MX2021010568A patent/MX2021010568A/es unknown
- 2020-03-02 IL IL321899A patent/IL321899A/en unknown
- 2020-03-02 PT PT207120296T patent/PT3934637T/pt unknown
- 2020-03-02 HU HUE20712029A patent/HUE068527T2/hu unknown
- 2020-03-02 ES ES20712029T patent/ES2990183T3/es active Active
-
2021
- 2021-09-02 MX MX2024015063A patent/MX2024015063A/es unknown
-
2024
- 2024-09-10 JP JP2024155453A patent/JP2024170602A/ja active Pending
-
2025
- 2025-06-30 AU AU2025204995A patent/AU2025204995A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55199B1 (fr) | (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| MXPA04004552A (es) | Compuestos tipo indolizina sustituida y metodos de uso. | |
| EA202190586A1 (ru) | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| WO2023081482A9 (en) | Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| TN2010000108A1 (fr) | Traitement de symtomes vasomoteurs | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
| ZA202205149B (en) | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| JP2021521227A5 (https=) | ||
| WO2022048618A8 (en) | Methods to treat inflammatory bowel disease | |
| ATE248607T1 (de) | Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen | |
| EA200702534A1 (ru) | Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2) | |
| MX2025012881A (es) | Compuestos heterociclicos biciclicos fusionados como moduladores del receptor tipo 4 de quimiocina c-c (ccr4) | |
| MX2025010543A (es) | Composiciones que comprenden 5-metoxi-2-aminoindan para el tratamiento de la depresion | |
| EA202092944A1 (ru) | Применение пероральных распадающихся таблеток рилузола для лечения заболеваний |